Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Adds New Zocor Warnings

By Drug Discovery Trends Editor | June 9, 2011

WASHINGTON (AP) – The Food and Drug Administration has added new warnings to the blockbuster cholesterol drug Zocor, cautioning doctors that the highest dose of the drug can cause muscle damage, including potentially lethal kidney damage in rare cases.

Regulators said Wednesday that patients taking the 80 milligram dose of Zocor, a statin drug, have a higher risk of muscle damage than patients taking lower doses of the drug or similar medications. The warning also applies to generic versions of the drug.

The 80 milligram dose should be continued only in patients who have been taking it for more than a year without signs of injury. New patients should start on a lower dose, the agency said in an online statement.

More than 2.1 million patients in the U.S. received a prescription for the Merck drug or a generic equivalent last year, according to the FDA. Whitehouse Station, N.J.-based Merck & Co. said about 12 percent of patients currently take the highest dose of the drug.

“This is an important medicine for these patients because they are at the highest risk for heart disease,” said Dr. Michael Rosenblatt, chief medical officer for Merck. “Patients shouldn’t stop taking this medicine on their own. They should talk to their doctor.”

FDA-approved doses for the drug range from 5 milligrams to 80 milligrams.

The FDA said the warning is based on clinical trials, studies, reports of side effects by users and prescription data.

Patients suffering from the muscle injury, called myopathy, experience pain, tenderness, weakness and elevation of the muscle enzyme creatine kinase. The most serious form of the injury, called rhabdomyolysis, can cause fatal injury to the kidneys. The condition is rare in patients taking Zocor, affecting about 5 out of every 100,000 people taking the drug for a year.

Zocor, known chemically as simvastatin, is no longer a big seller for Merck because of cheaper generic versions. But the company reported sales of $2 billion last year for Vytorin, which combines simvastatin with another cholesterol drug, ezetimibe

Simvastatin, which is also part Abbott Laboratories’ drug Simcor, is sold by 11 generic drugmakers including Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries, and Novartis’ Sandoz division.

The FDA first issued an alert about muscle injury with Zocor in March.

Date: June 8, 2011
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE